Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Current Assets (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Current Assets readings, the most recent being $940.4 million for Q1 2026.

  • On a quarterly basis, Current Assets rose 37.14% to $940.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $940.4 million, a 37.14% increase, with the full-year FY2025 number at $894.0 million, up 43.36% from a year prior.
  • Current Assets hit $940.4 million in Q1 2026 for Catalyst Pharmaceuticals, up from $894.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $940.4 million in Q1 2026 to a low of $192.0 million in Q3 2023.
  • Median Current Assets over the past 5 years was $404.6 million (2024), compared with a mean of $475.6 million.
  • Biggest five-year swings in Current Assets: plummeted 31.63% in 2023 and later soared 184.33% in 2024.
  • Catalyst Pharmaceuticals' Current Assets stood at $320.8 million in 2022, then tumbled by 31.63% to $219.3 million in 2023, then soared by 184.33% to $623.6 million in 2024, then skyrocketed by 43.36% to $894.0 million in 2025, then increased by 5.19% to $940.4 million in 2026.
  • The last three reported values for Current Assets were $940.4 million (Q1 2026), $894.0 million (Q4 2025), and $852.5 million (Q3 2025) per Business Quant data.